On September 17, 2019, the Food and Drug Administration approved apalutamide (ERLEADA®, Janssen Biotech, Inc) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
In a new interview on the ASCO in Action podcast episode, ASCO President Dr. Howard A. “Skip” Burris discusses why he became an oncologist, the importance of mentors in his professional career, the most significant changes he’s witnessed in cancer care during the past three decades, and his vision and hope for the coming year as he serves in this top ASCO volunteer position.
The American Medical Association (AMA) and Manatt Health have released, “National Roadmap on State-Level Efforts to End the Opioid Epidemic,” an analysis identifying effective state policies against the national opioid epidemic.
On September 17, 2019, the Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (KEYTRUDA®, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.
During ASCO's upcoming Advocacy Summit, oncology care providers will urge lawmakers to improve clinical trial access, protect patients from unnecessary care delays, ensure acess to potentially lifesaving medications, and foster continued success of the MACRA program. ASCO members are invited to participate virtually through the ACT Network.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule that would loosen state reporting requirements and potentially threaten access to cancer care for Medicaid beneficiaries. ASCO believes all patients should have access to high-quality, high-value cancer care and is concerned that CMS’ proposal would jeopardize that access.
A new study in the Journal of Oncology Practice (JOP) comparing the use of subacute rehabilitation (SAR) instead of hospice referral since the availably of immunotherapy finds a growing number of people with cancer are being discharged to SAR, but approximately two-thirds do not receive further cancer therapy at any point. This research provides important insights for goals of care.
ASCO joined 370 health care groups in urging members of the U.S. House of Representatives to support the Improving Seniors’ Timely Access to Care Act (H.R. 3107). The bipartisan bill would help protect patients from unnecessary care delays by streamlining and standardizing prior authorization under Medicare Advantage (MA) and providing program oversight and transparency for MA beneficiaries.
A new JCO Clinical Cancer Informatics (JCO CCI) article highlights the challenges in and need for obtaining real-world evidence (RWE) for assessing the effectiveness of precision medicine therapies on areas such as survival, quality of life, costs, and health disparities. RWE can be difficult to obtain because of the ways in which data is entered into electronic health records; one proposed solution is the mCODE™ initiative.
Four abstracts are being featured in the press program for the 2019 Quality Care Symposium, which takes place September 6–7 in San Diego.
ASCO is seeking medical institutions in low- and middle-income countries (LMIC) in the Asia-Pacific region to organize one or two live educational courses per year as part of the Society’s International Cancer Corps (ICC). The request for proposals (RFP) process is now open, and all proposals are due December 1.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule regarding Secure Electronic Prior Authorization for Medicare Part D. Under the proposal, clinicians would be able to complete prior authorizations for Part D prescriptions online and through a more streamlined process.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the agency’s Request for Information (RFI) on Patients over Paperwork. ASCO’s comments provide the society’s perspective on improving the delivery of cancer care in a way that is beneficial for people with cancer and oncology professionals.
ASCO, through its Center for Research and Analytics (CENTRA®), has issued a request for research ideas from its members for projects that ASCO could conduct to develop generalizable new knowledge for the oncology community. Of particular need are research ideas that align with the priorities documented in Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer and ASCO’s Strategic Plan or policy priorities. All ideas must be submitted by September 30 using a brief survey.
ASCO, CancerLinQ LLC and its technology collaborator Concerto HealthAI, and data from the practices that participate in the CancerLinQ® platform will be a part of the upcoming “8th Annual Blueprint for Breakthrough Forum—Validating Real-World Endpoints for an Evolving Regulatory Landscape” forum hosted by Friends of Cancer Research on September 18 in Washington, D.C.